Case Report: A good response to furmonertinib second-line treatment of an advanced lung adenocarcinoma patient with a rare EGFR exon 20 N771_P772insH mutation: A case report and literature review

• Hoofdauteurs: Xiao Zhang (Auteur), Huan Han (Auteur), Jiuzhou Zhao (Auteur), Xiao Liu (Auteur), Jianbo Zhang (Auteur), Rui Sun (Auteur), Shaomei Li (Auteur), Baoxing Liu (Auteur), Hui Zhu (Auteur), Shuyue Jiao (Auteur), Xiang Li (Auteur), Hong Tang (Auteur)
• Formaat: Boek
• Gepubliceerd in: Frontiers Media S.A., 2022-08-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Background: Lung adenocarcinoma with the classical EGFR 19 deletion and exon 21 L858R point mutations has exhibited good responses to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment. However, the sensitivity of uncommon EGFR exon 20 insertion mutation to third-gener...